Moreover, CWP232291 treatment inhibits tumor growth in the 22Rv1 subcutaneous CRPC xenograft model in vivo, with a concomitant decrease in β-catenin and increased expression of caspase-3 [230]. This evidence concerns the gene CASP3 and neoplasm.